• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Taro Pharm Inds (NY: TARO )

42.97 UNCHANGED
Last Price Updated: 7:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 42.97
Bid (Size) 41.50 (1)
Ask (Size) 43.97 (50)
Prev. Close 42.97
Today's Range 42.97 - 42.97
52wk Range 33.88 - 45.76
Shares Outstanding 37,584,631
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 24, 2024
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
CORRECTING and REPLACING TARO Investors Have Opportunity to Lead Taro Pharmaceutical Industries Ltd. Securities Fraud Lawsuit with the Schall Law Firm
September 16, 2024
From The Schall Law Firm
Via Business Wire

Performance

YTD
+2.90%
+2.90%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+1.63%
+1.63%
1 Year
+22.42%
+22.42%

More News

Read More
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 16, 2024
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Earnings Preview For Taro Pharmaceutical Indus
January 24, 2024
Via Benzinga
Taro Pharmaceutical Indus Earnings Preview
October 25, 2023
Via Benzinga
TARO Stock Earnings: Taro Pharmaceutical Indus Reported Results for Q4 2024
May 20, 2024
Via InvestorPlace
Taro Provides Results for Year Ended March 31, 2024
May 20, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Taro to Release Full Year Results on May 20, 2024
May 15, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger
May 08, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
April 22, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
April 15, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
February 06, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rover Group, Inc. (Nasdaq - ROVR), M.D.C. Holdings, Inc. (NYSE - MDC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE - PGTI)
January 26, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
Taro Provides Results for December 31, 2023
January 25, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rover Group, Inc. (Nasdaq - ROVR), M.D.C. Holdings, Inc. (NYSE - MDC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE - PGTI)
January 22, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
Taro to Release Third Quarter Results on January 25, 2024
January 19, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Earnings Scheduled For January 25, 2024
January 25, 2024
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: M.D.C. Holdings, Inc. (NYSE - MDC), Cornerstone Financial Corporation (OTC - CFIC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE -
January 18, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
TARO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Taro Pharmaceutical Industries Ltd. Is Fair to Shareholders
January 17, 2024
From Halper Sadeh LLC
Via Business Wire
Taro Provides Results for September 30, 2023
October 26, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Earnings Scheduled For October 26, 2023
October 26, 2023
Via Benzinga
Taro to Release Second Quarter Results on October 26, 2023
October 19, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Taro Provides Results for the Quarter Ended June 30, 2023
July 26, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Taro to Release First Quarter Results on July 26, 2023
July 19, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023
June 30, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap